GlassScriptPhysician profile
Mark D Ewalt
NPI 1497998512
$38,398.92
in general payments reported to CMS, 2019-2025
5 companies · $27K in 2025
The $27K reported for 2025 was more than what 92% of Molecular Genetic Pathology (Pathology) providers received nationally (typical 2025 total: $225).
See the full distribution for Molecular Genetic Pathology (Pathology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $7,040 · 2021: $1,900 · 2023: $105 · 2024: $2,126 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $4,915 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,030.80 |
| Travel and Lodging | $4,914.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Food and Beverage | $513.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pillar Biosciences, INC | $21,349.66 | 2024-2025 | |
| Illumina, INC. | $7,962.36 | 2023-2025 | Oncology Testing |
| Acceleron Pharma, INC. | $7,040.00 | 2020 | |
| Eli Lilly and Company | $1,900.00 | 2021 | |
| Janssen Biotech, INC. | $146.90 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ewalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.